REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...
